Literature DB >> 1819685

The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma.

S Miyaura1, N Maki, W Byrd, J M Johnston.   

Abstract

We have previously reported that certain fetal tissues including the lung and kidney have an increased platelet-activating factor (PAF) content and enzymatic mechanism for its elevated biosynthesis during the latter stages of pregnancy. In contrast, in the maternal plasma compartment of both the rabbit and human, a decreased capacity to inactivate PAF has been demonstrated. The PAF acetylhydrolase in the fetal plasma is also suppressed. The present study was undertaken to determine the mechanism(s) involved in the regulation of PAF acetylhydrolase. The 17 alpha-ethynylestradiol was administered (intraperitoneal [i.p.] 2.5 mg/kg body wt 5 days) to female and male rats. The plasma PAF acetylhydrolase activity decreased 5-fold. A decrease was observed when a concentration of the estrogen as low as 50 micrograms/kg was employed. The injection of dexamethasone (i.p., 1.3 mg/kg body wt, 5 days) to male and female rats resulted in a 3-fold increase in the plasma PAF acetylhydrolase activity. The activity returned to the values prior to hormone treatment 4 days after cessation of treatment. Testosterone and progesterone were without effect on plasma acetylhydrolase activity. The change in PAF acetylhydrolase activity caused by estrogen and the glucocorticoid was reflected by a change in the activity in the HDL fraction and not due to the presence of an inhibitor or activator in the plasma of the hormone-treated animals. Human serum obtained from a group of women, in which the 17 beta-estradiol concentration was elevated in preparation for an in vitro fertilization procedure, showed an inverse relationship between the plasma estrogen concentration and the PAF acetylhydrolase activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1819685     DOI: 10.1007/BF02536494

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  37 in total

1.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.

Authors:  R J HAVEL; H A EDER; J H BRAGDON
Journal:  J Clin Invest       Date:  1955-09       Impact factor: 14.808

2.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine.

Authors:  M L Blank; F Snyder; L W Byers; B Brooks; E E Muirhead
Journal:  Biochem Biophys Res Commun       Date:  1979-10-29       Impact factor: 3.575

3.  Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects.

Authors:  N Tamura; D K Agrawal; F A Suliaman; R G Townley
Journal:  Biochem Biophys Res Commun       Date:  1987-02-13       Impact factor: 3.575

4.  Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators).

Authors:  C A Demopoulos; R N Pinckard; D J Hanahan
Journal:  J Biol Chem       Date:  1979-10-10       Impact factor: 5.157

5.  Platelet-activating factor contracts human myometrium in vitro.

Authors:  C Tetta; G Montrucchio; G Alloatti; C Roffinello; G Emanuelli; C Benedetto; G Camussi; M Massobrio
Journal:  Proc Soc Exp Biol Med       Date:  1986-12

Review 6.  Platelet-activating factor: a paracrine factor in preimplantation stages of reproduction?

Authors:  M J Harper
Journal:  Biol Reprod       Date:  1989-05       Impact factor: 4.285

7.  Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats.

Authors:  M L Blank; M N Hall; E A Cress; F Snyder
Journal:  Biochem Biophys Res Commun       Date:  1983-06-15       Impact factor: 3.575

8.  Induction of leukocytic infiltrates in rabbit skin by acetyl glyceryl ether phosphorylcholine.

Authors:  D M Humphrey; D J Hanahan; R N Pinckard
Journal:  Lab Invest       Date:  1982-09       Impact factor: 5.662

9.  Enhanced degradation of platelet-activating factor in serum from diabetic patients.

Authors:  B Hofmann; K Rühling; P Spangenberg; G Ostermann
Journal:  Haemostasis       Date:  1989

10.  1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants.

Authors:  J T O'Flaherty; R L Wykle; C H Miller; J C Lewis; M Waite; D A Bass; C E McCall; L R DeChatelet
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

View more
  9 in total

Review 1.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

2.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study.

Authors:  Emmanouil S Brilakis; Amit Khera; Darren K McGuire; Raphael See; Subhash Banerjee; Sabina A Murphy; James A de Lemos
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

Review 4.  Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

5.  Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.

Authors:  Ida J Hatoum; Jeanenne J Nelson; Nancy R Cook; Frank B Hu; Eric B Rimm
Journal:  Am J Clin Nutr       Date:  2010-01-27       Impact factor: 7.045

6.  Prediction of Lipoprotein-Associated Phospholipase A2 and Inflammatory Markers in Subclinical Atherosclerosis in Premature Ovarian Failure Patients.

Authors:  Yusuf Cekici; Salih Kilic; Ali Ovayolu; Erhan Saracoglu; İrfan Veysel Duzen; Mucahid Yilmaz; Bedri Caner Kaya; Devrim Bozkurt
Journal:  Acta Cardiol Sin       Date:  2021-01       Impact factor: 2.672

7.  Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.

Authors:  Youxin Wang; Bin Zhou; Pingan Zhou; Yan Yao; Qinghua Cui; Yingping Liu; Jichun Yang; Shouling Wu; Xingquan Zhao; Yong Zhou
Journal:  J Cell Mol Med       Date:  2018-02-09       Impact factor: 5.310

8.  The relationship between dietary patterns and lipoprotein-associated phospholipase A2 levels in adults with cardiovascular risk factors: Tehran Lipid and Glucose Study.

Authors:  Seyed Hashem Sezavar Seyedi; Azadeh Mottaghi; Parvin Mirmiran; Mehdi Hedayati; Fereidoun Azizi
Journal:  J Res Med Sci       Date:  2020-01-20       Impact factor: 1.852

9.  Maternal Gestational Diabetes Mellitus increases placental and foetal lipoprotein-associated Phospholipase A2 which might exert protective functions against oxidative stress.

Authors:  Carolin Schliefsteiner; Birgit Hirschmugl; Susanne Kopp; Sanja Curcic; Eva Maria Bernhart; Gunther Marsche; Uwe Lang; Gernot Desoye; Christian Wadsack
Journal:  Sci Rep       Date:  2017-10-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.